Switzerland fast-tracks antiviral medication against Covid-19
Remdesivir has already been granted temporary approval in other countries.
Keystone / Marcel Kusch
The Swiss health authorities have granted approval for the remdesivir drug in “record time” for treating coronavirus patients. The temporary authorisation to widen the use of the antiviral drug will be closely monitored in case of adverse side effects.
This content was published on
2 minutes
swissinfo.ch/mga
Swissmedic, the agency that oversees the use of medicaments in Switzerland, took days to fast-track approval of the drug, which is produced under the brand name Veklury by US biopharmaceutical company Gilead Sciences. The application for its extended use was only received on Monday.
It can now be used for a limited period of time to treat patients suffering from SARS-CoV-2-related pneumonia who also require oxygen.
The drug has been authorized for emergency use in the United States, India, Singapore, South Korea and Japan and has been recommended by the European Medicines Agency to treat coronavirus patients in the EU.
Swissmedic said on Thursday that it had conducted a “careful review in record time” of the drug. Hospital doctors have now been given the green light to administer the treatment. “Adverse reactions to the drug will be closely monitored in order to ensure patient safety,” read a statement.
“The product will also be made available to patients outside approved clinical trials and the approved compassionate use programme while the submitted authorisation application is being reviewed,” it added.
Clinical trials in the US on medicaments containing the active ingredient remdesivir found that the hospital stay of severely affected Covid-19 patients was shortened in almost a third of cases.
Should raw milk sales be banned or should consumers decide?
Swiss food regulations do not allow raw milk to be sold for direct consumption. However, a loophole allows 400 raw milk vending machines to do just that.
Personal care products affect indoor air quality, warns Swiss study
This content was published on
A Swiss study claims that typical personal care products can have a ‘significant impact’ on air quality when used in enclosed spaces.
Government estimates for first time Switzerland’s carbon budget up to 2050
This content was published on
The Swiss government predicts that the country will produce around 660 million tonnes of CO2 equivalents for the 2020-2050 period if it meets its climate targets.
Switzerland imposes entry ban on far-right Austrian activist Martin Sellner
This content was published on
Switzerland has imposed an entry ban on the far-right Austrian extremist Martin Sellner. This prevents him from speaking at an event planned by the Swiss Junge Tat far-right group in canton Zurich.
Security firm Sicpa cuts jobs in western Switzerland
This content was published on
Sicpa, a company specialising in security inks, announced on Thursday that it plans to cut up to 120 jobs in canton Vaud, citing a complicated international economic context and geopolitical tensions.
UK resumes trade talks with Switzerland in ‘Global Britain’ push
This content was published on
British and Swiss trade negotiators will resume trade talks on Monday as they seek to broker deeper access to each other’s financial services markets as well as agreements on data sharing and worker visas.
Swiss army suspends CHF320m project for airspace surveillance
This content was published on
The Swiss parliament approved almost CHF320 million for "Skyview" airspace surveillance system. The reason for the suspension is problems with the integration of the system.
Murdered student: Paris asks Bern to extradite suspect
This content was published on
On Wednesday, France submitted an extradition request to the Swiss authorities for the man suspected of murdering Philippine. This was announced Thursday morning by the French Minister of Justice, Didier Migaud, on BFMTV.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Sixteen Swiss hospitals take part in coronavirus global Solidarity trial
This content was published on
Some 1,000 patients in Switzerland are expected to participate in trials of experimental treatments for Covid-19 as part of global Solidarity trial.
Fight over rights to Covid-19 drugs puts Switzerland in a tough spot
This content was published on
As calls mount for equitable access, Switzerland is caught between established practice and global solidarity in how to encourage medical innovation.
This content was published on
Swiss scientists and drug companies are playing an important role in the global effort to develop treatments or a vaccine for the virus.
Swiss hospitals launch drug trial to prevent Covid-19 infection
This content was published on
Researchers in Geneva and Basel have launched a clinical trial to test two drugs on people that have been in contact with Covid-19 patients.
Novartis steps up coronavirus fight as part of new collaboration
This content was published on
Several big pharmaceutical companies have joined forces with the Bill & Melinda Gates Foundation in response to the coronavirus pandemic.
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
Covid-19 is both threat and opportunity for Swiss biotech
This content was published on
Although the coronavirus pandemic is the Swiss biotech industry’s time to shine, it has left many smaller firms struggling to survive.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.